SAN DIEGO--(BUSINESS WIRE)--AltheaDx, Inc. today announced a significant expansion to the neuropsychiatric component of its IDgenetix® pharmacogenetic (PGx) testing portfolio, NeuroIDgenetix™. The NeuroIDgenetix™ panel now includes PGx testing for medications used to treat both bipolar disorder and seizure disorder. Bipolar disorder affects approximately 5.7 million adult Americans on an annual basis, while approximately 4.3 million adults have a diagnosis of epilepsy or a seizure disorder every year. 1,2
